In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma.We provide one additional year of follow up and include the effect on Baby minimal residual disease and in clinically relevant subgroups.After 25.
4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival Panier Bike Seats versus lenalidomide/dexamethasone alone (median not reached vs.17.5 months; hazard ratio, 0.
41; 95% confidence interval, 0.31-0.53; P.